{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:56:07Z","timestamp":1760316967110,"version":"build-2065373602"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3<\/jats:italic>\u2010mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce.<\/jats:p><\/jats:sec>Methods<\/jats:title>Clinical data are reported from 394 ND patients with FLT3<\/jats:italic>\u2010mutated AML enrolled in the retrospective observational Italian Cohort Study on FLT3<\/jats:italic>\u2010mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, n<\/jats:italic>\u00a0=\u00a092) or without (CT group, n<\/jats:italic>\u00a0=\u00a0302) the addition of a FLT3i.<\/jats:p><\/jats:sec>Results<\/jats:title>With a median follow\u2010up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, p<\/jats:italic>\u00a0<\u00a0.01) and relapse\u2010free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, p<\/jats:italic>\u00a0=\u00a0.01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, p<\/jats:italic>\u00a0=\u00a0.052). FLT3i benefit seemed to be independent from the transplant rate.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3\u2010mutated AML patients was confirmed in a large, real\u2010life cohort study.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35824","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:09:02Z","timestamp":1743433742000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upfront intensive treatment analysis of the Italian Cohort Study on FLT3<\/i>\u2010mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real\u2010life setting"],"prefix":"10.1002","volume":"131","author":[{"given":"Jacopo","family":"Nanni","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche Istituto di Ematologia \u201cSer\u00e0gnoli\u201d University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-7044","authenticated-orcid":false,"given":"Irene","family":"Azzali","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-8333","authenticated-orcid":false,"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Mul\u00e8","sequence":"additional","affiliation":[{"name":"U.O.C. di Oncoematologia A.O.O.R. Villa Sofia \u2013 Cervello Palermo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesta","family":"Audisio","sequence":"additional","affiliation":[{"name":"SC Ematologia 2 Dipartmento di Ematologia e Oncologia AO Citt\u00e0 della Salute e della Scienza Torino Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Center for Hemato\u2010Oncology Research University of Perugia and Santa Maria della Misericordia Hospital Perugia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Scappini","sequence":"additional","affiliation":[{"name":"AOU Careggi SODc Ematologia Firenze Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Radiologiche ed Ematologiche Universit\u00e0 Cattolica del Sacro Cuore Roma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Camb\u00f2","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery Hematology and BMT Unit University of Parma Parma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[{"name":"Clinica Ematologica Azienda Sanitaria Universitaria Integrata di Udine Udine Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Lunghi","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Translational Medicine Universit\u00e0 del Piemonte Orientale Novara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe\u2010J) Hematology and Stem Cell Transplantation Unit University of Bari \u201cAldo Moro\u201d Bari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia AOU Ospedali Riuniti di Ancona Ancona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Fracchiolla","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda\u2010Ospedale Maggiore Policlinico di Milano Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Bernardi","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale San Raffaele s.r.l U.O. Ematologia e TMO Milano Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Romani","sequence":"additional","affiliation":[{"name":"SC Ematologia e CTMO Azienda Ospedaliera Brotzu Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-5190","authenticated-orcid":false,"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[{"name":"Hematology St. Anna University Hospital Ferrara Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Benedetta","family":"Giannini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Hematology Unit University of Siena Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Todisco","sequence":"additional","affiliation":[{"name":"European Institute of Oncology Milano Italy"},{"name":"S.C. di Ematologia e Trapianto di Cellule Staminali Emopoietiche Ospedale di Busto Arsizio ASST Valle Olona Busto Arsizio (VA) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Cliniche e Biologiche Universit\u00e0 di Torino S.S.D Terapia onco\u2010ematologica intensiva e trapianto CSE AOU San Luigi Gonzaga Orbassano (TO) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Bochicchio","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche Istituto di Ematologia \u201cSer\u00e0gnoli\u201d University of Bologna Bologna Italy"},{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Mattei","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6129-6656","authenticated-orcid":false,"given":"Federica","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Valli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Volpi","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Petracci","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"FLAM Collaborative Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d (IRST) Meldola (FC) Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.09.22271087"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010733196"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.240754"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.11.005"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061115"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1097\u20102765(03)00505\u20107"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4326"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535\u20106108(02)00069\u20107"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614359"},{"key":"e_1_2_11_14_1","unstructured":"FDA.Midostaurin (Rydapt) USPI.2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/s0167676800003524"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1805109"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007223"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)00464\u20106"},{"key":"e_1_2_11_19_1","unstructured":"U.S. Food and Drug Administration.VANFLYTA\u00ae (quizartinib) tablets for oral use initial U.S. approval.2023.www.fda.gov\/medwatch"},{"issue":"9","key":"e_1_2_11_20_1","first-page":"3074","article-title":"Prognostic implication of FLT3 and N\u2010RAS gene mutations in acute myeloid leukemia","volume":"93","author":"Kiyoi H","year":"1999","journal-title":"Blood"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201005\u20101440"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201004\u2010015826"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201008\u2010869453"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280161"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018886960"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010034"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.3302.3302"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201007\u2010235358"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002697"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201006\u2010431122"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.023"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:55:28Z","timestamp":1760298928000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/cncr.35824"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35824","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2025,3,30]]},"assertion":[{"value":"2024-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35824"}}